-
1 week ago | 
ajmc.com | Julia Bonavitacola |Eric M. Lander
Eric Lander, MD, site research leader at Minnesota Oncology, spoke with The American Journal of Managed Care®after participating in the Institute for Value-Based Medicine® meeting held in Minneapolis on June 17. The panel Lander participated on focused on several topics revolving around National Comprehensive Cancer Network guidelines and how their recommendations are practiced in real-world settings.
-
1 week ago | 
ajmc.com | Julia Bonavitacola |Gordon Crofoot
Cost could make lenacapavir (Sunlenca; Gilead) inaccessible for people who would like to use it as a means of pre-exposure prophylaxis (PrEP) in the prevention of HIV, explained Gordon Crofoot, MD, PA, president and principal investigator at The Crofoot Research Center. Although the treatment is nearly 100% effective, the price point could make rollout slow in vulnerable populations. This transcript has been lightly edited for clarity; captions are auto-generated.
-
1 week ago | 
ajmc.com | Julia Bonavitacola |Colleen Kelley
The prevention of HIV could monumentally shift followong the FDA approval of lenacapavir on June 19, as the twice-yearly long-acting injectable form of pre-exposure prophylaxis (PrEP) demonsstrated high efficacy in preventing HIV in early trials.
-
1 week ago | 
ajmc.com | Julia Bonavitacola
Author(s):Fact checked by: The current prior authorization process negatively impacts patient care, leading some practices to switch to a cash-only model. A report reveals that 45% of insured adults received unexpected medical bills for services they believed were covered. 17% of insured adults were denied coverage for services recommended by their physicians, highlighting systemic issues in health insurance.
-
1 week ago | 
ajmc.com | Julia Bonavitacola |Onyema Ogbuagu
The FDA approval of lenacapavir on June 19 offers a new treatment that can help to reduce the incidence of HIV globally, with approximately 100% efficacy when used as pre-exposure prophylaxis (PrEP) to prevent the incidence of HIV.
-
1 week ago | 
ajmc.com | Julia Bonavitacola |Timothy J. Craig
Timothy Craig, DO, professor at Penn State University and principal investigator of the VANGUARD phase 3 trial (NCT04656418) on garadacimab, discussed the safety profile of garadacimab, which was approved for use in patients with hereditary angioedema (HAE) on June 17, and sebetralstat, which is awaiting FDA approval for use as rescue medication in patients with HAE. This transcript has been edited for clarity; captions are auto-generated.
-
1 week ago | 
ajmc.com | Julia Bonavitacola |Eric M. Lander
Eric Lander, MD, site research leader at Minnesota Oncology, spoke with The American Journal of Managed Care®after participating in the Institute for Value-Based Medicine® meeting held in Minneapolis on June 17. The panel Lander participated in focused on several topics revolving around NCCN guidelines and how their recommendations are practiced in real-world settings.
-
1 week ago | 
ajmc.com | Julia Bonavitacola |Gordon Crofoot
Gordon Crofoot, MD, PA, president and principal investigator at The Crofoot Research Center, emphasized how much lenacapavir could change the landscape of HIV care with its approval by the FDA for use as pre-exposure prophylaxis (PrEP). This approval could help to eradicate HIV if it is made available for those at the highest risk of contracting and transmitting the virus, he said. This transcript has been lightly edited for clarity; captions were auto-generated.
-
1 week ago | 
ajmc.com | Julia Bonavitacola
Prevention of HIV has become even easier with the FDA approval of lenacapavir (Yeztugo; Gilead Sciences), a twice-yearly long-acting injectable treatment that can prevent HIV in those who receive the treatment.1 For those who prefer an injectable form of pre-exposure prophylaxis (PrEP), this approval reduces the number of injections needed from 6 per year to just 2, potentially improving adherence in those who had difficulty attending bimonthly clinic appointments.
-
1 week ago | 
ajmc.com | Julia Bonavitacola |Timothy J. Craig
Timothy Craig, DO, professor at Penn State University and principal investigator of the VANGUARD phase 3 trial (NCT04656418) of garadicamab, believes that garadacimab can be taken in combination with sebetralstat, which is a medication that can offer rescue assistance for patients with hereditary angioedema (HAE). This transcript was edited for clarity; captions are auto-generated. TranscriptAre there differences between garadacimab and sebetralstat when it comes to treating HAE?
